Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SERPASIL-ESIDRIX #1

HYDROCHLOROTHIAZIDE; RESERPINE

Standard Dose
25MG;0.1MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview SERPASIL-ESIDRIX #1 is listed in Drugs@FDA under application 011878 (NDA).

Marketing status: Discontinued Active ingredient HYDROCHLOROTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 25MG;0.1MG Sponsor NOVARTIS Submission history Latest submission status date: 1987-05-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview SERPASIL-ESIDRIX #1 is listed in Drugs@FDA under application 011878 (NDA). Marketing status: Discontinued Active ingredient HYDROCHLOROTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 25MG;0.1MG Sponsor NOVARTIS Submission history Latest submission status date: 1987-05-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.